References
- SiegelRLMillerKDJemalAStatisticsCCA Cancer J Clin2017201767730
- SahaSKZhuAXFuchsCSBrooksGAForty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the riseOncologist201621559459927000463
- NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines®)Hepatobiliary Cancers Version 1 [EB/OL] [2018-02-14] Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#hepatobiliary
- KornekGVSchuellBLaengleFMitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trialAnn Oncol200415347848314998852
- DucreuxMvan CutsemEvan LaethemJLA randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trialEur J Cancer200541339840315691639
- ValleJWasanHPalmerDHCisplatin plus gemcitabine versus gemcitabine for biliary tract cancerN Engl J Med2010362141273128120375404
- OkusakaTNakachiKFukutomiAGemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in JapanBr J Cancer2010103446947420628385
- BorbathICerattiAVerslypeCCombination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive OncologyAnn Oncol2013242824282923975665
- MoehlerMMadererASchimanskiCGemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programmeEur J Cancer201450183125313525446376
- ValleJWWasanHLopesACediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trialLancet Oncol201516896797826179201
- BorgerDRTanabeKKFanKCFrequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotypingOncologist2012171727922180306
- WangPDongQZhangCMutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomasOncogene201332253091310022824796
- VossJSHoltegaardLMKerrSEMolecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisionsHum Pathol20134471216122223391413
- ChuriCRShroffRWangYMutation profiling in cholangiocarcinoma: prognostic and therapeutic implicationsPLoS One2014912e11538325536104
- RossJSWangKGayLNew routes to targeted therapy of intra-hepatic cholangiocarcinomas revealed by next-generation sequencingOncologist201419323524224563076
- GrahamRPBarr FritcherEGPestovaEFibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinomaHum Pathol20144581630163824837095
- AraiYTotokiYHosodaFFibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinomaHepatology20145941427143424122810
- JavleMLoweryMShroffRTPhase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinomaJ Clin Oncol2018363JCO2017755009
- MazzaferroVDrozMBussetDARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations[C] Poster-ASCO-2017;4017NO
- HymanDMPuzanovISubbiahVVemurafenib in multiple nonmelanoma cancers with BRAF V600 mutationsN Engl J Med2015373872673626287849
- HainsworthJDMeric-BernstamFSwantonCTargeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket studyJ Clin Oncol2018344_supplJCO2017753780542
- KaufmanBShapira-FrommerRSchmutzlerRKOlaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationJ Clin Oncol201533324425025366685
- TomczakKCzerwińskaPWiznerowiczMThe Cancer Genome Atlas (TCGA): an immeasurable source of knowledgeContemp Oncol2015191A6877